Provided by Tiger Fintech (Singapore) Pte. Ltd.

Estrella Immunopharma

1.50
+0.210016.28%
Post-market: 1.500.00000.00%19:57 EDT
Volume:313.22K
Turnover:440.11K
Market Cap:55.60M
PE:-4.53
High:1.50
Open:1.33
Low:1.32
Close:1.29
52wk High:1.78
52wk Low:0.6300
Shares:37.07M
Float Shares:10.99M
Volume Ratio:1.52
T/O Rate:2.85%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.3309
EPS(LYR):-0.1212
ROE:-268.50%
ROA:-100.93%
PB:-9.12
PE(LYR):-12.37

Loading ...

Company Profile

Company Name:
Estrella Immunopharma
Exchange:
NASDAQ
Establishment Date:
2006
Employees:
- -
Office Location:
5858 Horton Street,Suite 370,EmeryVille,California,United States
Zip Code:
94608
Fax:
- -
Introduction:
Estrella Immunopharma, Inc., a clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103, which is in clinical trial, for the treatment of diffuse large B-cell lymphoma; EB104, which is in pre-clinical trial, to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia; and EB201, which is in pre-clinical trial, for the treatment of systemic lupus erythematosus. It has a collaborative agreement with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. was founded in 2006 and is headquartered in EmeryVille, California.

Directors

Name
Position
Cheng Liu
Chief Executive Officer, President and Director
Hong Zhang
Director and Chairperson of the Board
Dengyao Jia
Director
Fan Wu
Director
Janelle Wu
Director
Marsha Roberts
Director
Pei Xu
Director

Shareholders

Name
Position
Cheng Liu
Chief Executive Officer, President and Director
Peter Xu
Chief Financial Officer